Schluger, N. W. 2008. Improving protection for human research subjects: Better oversight, not just more oversight. American Journal of Bioethics 8(11):13-15.

Stang, P. E., P. B. Ryan, J. A. Racoosin, J. M. Overhage, A. G. Hartzema, C. Reich, E. Welebob, T. Scarnecchia, and J. Woodcock. 2010. Advancing the science for active surveillance: Rationale and design for the observational medical outcomes partnership. Annals of Internal Medicine 153(9):600-606.

Stolberg, H. O., G. Norman, and I. Trop. 2004. Randomized controlled trials. American Journal of Roentgenology 183(6):1539-1544.

Strom, B.L. 2005. Pharmacoepidemiology, Fourth Edition. John Wiley and Sons: Hoboken, NJ.

Temple, R., and S. S. Ellenberg. 2000. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues. Annals of Internal Medicine 133(6):455-463.

Thiers, F. A., A. J. Sinskey, and E. R. Berndt. 2008. Trends in the globalization of clinical trials. Nature Reviews Drug Discovery 7:13-14.

Truog, R. D., W. Robinson, A. Randolph, and A. Morris. 1999. Is informed consent always necessary for randomized, controlled trials? New England Journal of Medicine 340(10):804-807.

Van Assche, G., M. Van Ranst, R. Sciot, B. Dubois, S. Vermeire, M. Noman, J. Verbeeck, K. Geboes, W. Robberecht, and P. Rutgeerts. 2005. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. New England Journal of Medicine 353(4):362-368.

Vandenbroucke, J. P., and B. M. Psaty. 2008. Benefits and risks of drug treatments: How to combine the best evidence on benefits with the best data about adverse effects. JAMA 300(20):2417-2419.

Wadman, M. 2007. Biomedical philanthropy: State of the donation. Nature 447(7142):248-250.

Wendler, D. 2009. Must research participants understand randomization? American Journal of Bioethics 9(2):3-8.

Wittes, J., E. Barrett-Connor, E. Braunwald, M. Chesney, H. J. Cohen, D. DeMets, L. Dunn, J. Dwyer, R. P. Heaney, V. Vogel, L. Walters, and S. Yusuf. 2007. Monitoring the randomized trials of the Women’s Health Initiative: The experience of the Data and Safety Monitoring Board. Clinical Trials 4(3):218-234.

The National Academies of Sciences, Engineering, and Medicine
500 Fifth St. N.W. | Washington, D.C. 20001

Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement